SCHEMBL10089889

SCHEMBL10089889

Cc1cc(C#N)cc(C(=O)NC2CCSCC2)c1NC(=O)c1cc(Cn2nnc(C(F)(F)F)n2)nn1-c1ccccc1Cl

nearest known ligand 0.34

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.34
RORC P51449 3/20 0.33
SLC2A1 P11166 3/20 0.32
SLC2A3 P11169 3/20 0.32
SLC2A4 P14672 3/20 0.32
MAPK14 Q16539 1/20 0.32
SLC16A3 O15427 4/20 0.32
SLC16A1 P53985 4/20 0.32
CRHR1 P34998 3/20 0.31
ADORA1 P30542 1/20 0.31
PDE4B Q07343 1/20 0.31
CRHR2 Q13324 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13085376 0.96 CNR1 (0.37) CNR1RORCSLC2A1SLC2A3SLC2A4
SCHEMBL10089947 0.94 CNR1 (0.38) CNR1RORCSLC2A1SLC2A3SLC2A4
SCHEMBL10089952 0.94 SLC2A1 (0.34) CNR1RORCSLC2A1SLC2A3SLC2A4
SCHEMBL10089919 0.93 ELANE (0.36) CNR1RORC
SCHEMBL10089843 0.91 RORC (0.39) CNR1RORCSLC2A1SLC2A3SLC2A4
SCHEMBL15905591 0.90 ELANE (0.38)
SCHEMBL10083881 0.88 SLC2A1 (0.35) CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL13085496 0.88 CETP (0.35) CNR1SLC2A1SLC2A3SLC2A4SLC16A3
SCHEMBL10076311 0.87 SLC2A1 (0.35) CNR1SLC2A1SLC2A3SLC2A4SLC16A3
SCHEMBL13085547 0.87 SLC2A1 (0.35) CNR1SLC2A1SLC2A3SLC2A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791143-B2 Anthranilic diamide derivatives having cyclic side-chains BAYER CROPSCIENCE AG (DE) 2014-07-29 US disclosed
US-20120010249-A1 Anthranilic diamide derivatives having cyclic side-chains BAYER CROPSCIENCE AG (DE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010249-A1 Anthranilic diamide derivatives having cyclic side-chains DDT, ADCY1, ANTXR2 CNR1 984/4885RORC 3664/4885SLC2A1 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.